TC BioPharm Limited Quarterly report pursuant to Section 13 or 15(d)

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2024

The Company has granted options over ADSs to certain employees.

SCHEDULE OF GRANTED OPTIONS

	Number of Share Options		Weighted Average Exercise Price
Outstanding at December 31, 2023		5,328	£	460
Granted during the period		-		-
Exercised during the period		-		-
Forfeited during the period		-		-
Outstanding at March 31, 2024		5,328	£	460

Exerciseable at March 31, 2024		5,328	£	460
Unexerciseable at March 31, 2024		-		-

The Company has granted options over ADSs to certain employees and directors.

*	Number of Share Options			Weighted Average Exercise Price
Outstanding at December 31, 2023		37,066		$	230
Granted during the period		999,838			1.07
Exercised during the period		(121,070	)		.0025
Cancelled during the period		(933	)		4,240
Outstanding at March 31, 2024		914,901		$	6.01

Exerciseable at March 31, 2024		914,901		$	6.01
Unexerciseable at March 31, 2024		-			-